Evidence map›Paper›PMID 33268820›Full record

ArticleLeukemia2021

Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.

Su-Min Jeong, Taewoong Choi, Dahye Kim, Kyungdo Han, Seok Jin Kim, Sang Youl Rhee, Edward L Giovannucci, Dong Wook Shin

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. [Progress in metabolomics of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Su-Min Jeong *Department of Family Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-9588-1928
Taewoong Choi *Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-3776-2407
Dahye KimDepartment of Medical Statistics, The Catholic University of Korea, Seoul, Republic of Korea.
Kyungdo HanDepartment of Medical Statistics, The Catholic University of Korea, Seoul, Republic of Korea.
Seok Jin KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sang Youl RheeDepartment of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
Edward L GiovannucciDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
Dong Wook ShinSupportive Care Center/Department of Family Medicine, Samsung Medical Center, Seoul, Republic of Korea. dwshin.md@gmail.com.ORCID http://orcid.org/0000-0001-8128-8920
Catholic University of Korea · KRBrigham and Women's Hospital · USDuke Medical Center · USHanwha Techwin (South Korea) · KRHarvard University · USSamsung Medical Center · KRScripps Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the relationships between HDL-C and major types of blood cancers. Competing risks regression was used to examine the hazard ratios of hematologic malignancies in 9,596,145 individuals (≥20 years) using data from the Korean National Health Insurance Service (2009-2017). The incidence of the following hematologic cancers was determined based on the International Classification of Diseases 10th revision: Multiple Myeloma (MM), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Lymphoid Leukemia (LL), and Myeloid Leukemia (ML). During an average of 8.3 years of follow-up (79,179,225 person-years), 15,864 incident hematologic malignancies were identified. Compared to those in the highest HDL-C quartile, subjects in the lowest HDL-C quartile had the highest risk of all hematologic cancers combined (adjusted hazard ratio [HR], 95% confidence interval [95% CI] = 1.31, 1.25-1.37) and of each respective type of blood cancer, as follows: MM (HR 1.61, 95% CI, 1.46-1.76), HL (HR 1.35, 95% CI 1.07-1.70), NHL (HR 1.12, 95%CI 1.04-1.21), LL (HR 1.36, 95% CI 1.16-1.61), and ML (HR 1.33, 95% CI 1.22-1.45). Low HDL-C level was significantly associated with increased risk of hematologic malignancy, suggesting that a low HDL-C level is an independent risk factor and preclinical marker for hematologic malignancy.

Indexed as

FemaleHematologic NeoplasmsHumansIncidenceLipoproteins, HDLMaleMiddle AgedProportional Hazards ModelsRisk FactorsLipoproteins, HDL

Identifiers

PMID33268820
OpenAlexW3108223938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.